Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Assess the Renoprotective Effects of the SGLT2 Inhibitor Dapagliflozin in Non-Diabetic Patients With Proteinuria: a Randomized Double Blind 6-Weeks Cross-Over Trial

NCT03190694 is registered in ClinicalTrials.gov with Hiddo Lambers Heerspink as lead sponsor.

NCT NCT03190694
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03190694 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Assess the Renoprotective Effects of the SGLT2 Inhibitor Dapagliflozin in Non-Diabetic Patients With Proteinuria: a Randomized Double Blind 6-Weeks Cross-Over Trial
Lead sponsor
Hiddo Lambers Heerspink
Phase
Phase 2
Overall status
Completed
Start date
November 12, 2017
Completion date
December 1, 2019
Enrollment
53 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney diseases, proteinuria